172 related articles for article (PubMed ID: 32907896)
1. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.
Wade J; Donovan J; Lane A; Davis M; Walsh E; Neal D; Turner E; Martin R; Metcalfe C; Peters T; Hamdy F; Kockelbergh R; Catto J; Paul A; Holding P; Rosario D; Kynaston H; Rowe E; Hughes O; Bollina P; Gillatt D; Doherty A; Gnanapragasam VJ; Paez E
BMJ Open; 2020 Sep; 10(9):e036024. PubMed ID: 32907896
[TBL] [Abstract][Full Text] [Related]
2. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
3. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
4. Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.
Wade J; Holding PN; Bonnington S; Rooshenas L; Lane JA; Salter CE; Tilling K; Speakman MJ; Brewster SF; Evans S; Neal DE; Hamdy FC; Donovan JL;
BMJ Open; 2015 Sep; 5(9):e008953. PubMed ID: 26384727
[TBL] [Abstract][Full Text] [Related]
5. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
8. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
[TBL] [Abstract][Full Text] [Related]
11. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
Tilling K; Garmo H; Metcalfe C; Holmberg L; Hamdy FC; Neal DE; Adolfsson J; Martin RM; Davis M; Fall K; Lane JA; Adami HO; Bill-Axelson A; Johansson JE; Donovan JL
Eur Urol; 2010 Mar; 57(3):446-52. PubMed ID: 19303695
[TBL] [Abstract][Full Text] [Related]
12. A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer.
Bates AS; Kostakopoulos N; Ayers J; Jameson M; Todd J; Lukha R; Cymes W; Chasapi D; Brown N; Bhattacharya Y; Paterson C; Lam TBL
Semin Oncol Nurs; 2020 Aug; 36(4):151045. PubMed ID: 32703714
[TBL] [Abstract][Full Text] [Related]
13. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
[TBL] [Abstract][Full Text] [Related]
14. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
[TBL] [Abstract][Full Text] [Related]
15. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
16. Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial.
Wade J; Rosario DJ; Howson J; Avery KN; Salter CE; Goodwin ML; Blazeby JM; Lane JA; Metcalfe C; Neal DE; Hamdy FC; Donovan JL
BMC Health Serv Res; 2015 Feb; 15():80. PubMed ID: 25889315
[TBL] [Abstract][Full Text] [Related]
17. Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.
Dordoni P; Remmers S; Valdagni R; Bellardita L; De Luca L; Badenchini F; Marenghi C; Roobol MJ; Venderbos LDF
BMC Urol; 2022 Jul; 22(1):110. PubMed ID: 35850672
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
Simpkin AJ; Tilling K; Martin RM; Lane JA; Hamdy FC; Holmberg L; Neal DE; Metcalfe C; Donovan JL
Eur Urol; 2015 Jun; 67(6):993-1005. PubMed ID: 25616709
[TBL] [Abstract][Full Text] [Related]
19. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
